In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

EHJ - Cardiovascular Pharmacotherapy

Specific focus on clinical cardiovascular pharmacology

 

The European Heart Journal - Cardiovascular Pharmacotherapy (EHJ-CVP) is the official journal of the European Society of Cardiology and the ESC Working Group on Cardiovascular Pharmacotherapy. The journal aims to improve the pharmacological treatment of patients with cardiovascular disease through interpreting and integrating new scientific developments within this area.

It publishes original articles concerning clinical research, with new and established drugs and methods, as well as meta-analysis and topical reviews.

Fast Facts

  • Editor-in-Chief: Stefan Agewall FESC, NO
  • Current volume: 3 (year 2017)
  • Issues per subscription: 4
Updates on latest articles

Updates on latest articles

 

Receive Table of contents in your mailbox.

Track the topics, authors and articles important to you and receive articles in your mailbox.

For Authors

Before being published, all manuscripts go through double-blinded peer review by experienced international experts.


Most recent articles from EHJ-CVP

05 Mar 2018
Cardiovascular pharmacotherapy and real-world data
Author(s):Agewall S.
05 Mar 2018
How does the TRS 2°P score relate to real-world patients?
Author(s):Bonaca M, De Ferrari G, Atar D, et al.
05 Mar 2018
Trimetazidine: is there a role beyond angina?
Author(s):Tarkin J, Kaski J.
30 Jan 2018
Trends in optimal medical therapy prescription and mortality after admission for acute coronary syndrome: a 9-year experience in a real-world setting
Author(s):Hoedemaker N, Damman P, Ottervanger J, et al.